News & Updates

Chronic obstructive pulmonary disease (COPD) patients initiating treatment with a long-acting muscarinic antagonist (LAMA) plus a long-acting β2-agonist (LABA) tend to have higher disease severity than those who are started on LAMA, according to real-world data from Singapore. However, there are as many patients who experience clinical worsening in the LAMA group as there are in the LAMA+LABA group.

People who inject drugs (PWID) and are receiving treatment for hepatitis C virus (HCV) show a substantial decline in liver disease and mortality, according to a study.

Psoriatic arthritis (PsA) patients with moderate disease activity (MDA) at baseline who are treated with apremilast are more likely to achieve treatment targets than those with high disease activity (HDA), a recent study has shown.

There are currently 40 approved vaccines against COVID-19, of which 11 have been granted Emergency Use Authorization by the World Health Organization. [covid19.trackvaccines.org/vaccines/approved] With over 300 other candidates in the development pipeline – over 100 of which are in clinical testing [vac-lshtm.shinyapps.io/ncov_vaccine_landscape] – are new vaccines necessary?

Treatment with the combination of ribociclib plus binimetinib appears to be well tolerated and delivers modest clinical activity in patients with locally advanced or metastatic melanoma harbouring NRAS mutation, according to the results of a phase Ib/II study.

A novel nitric oxide-releasing gel, berdazimer 10.3%, proves effective in the treatment of patients with water warts or molluscum contagiosum skin infection, facilitating clearance of lesions with low adverse event rates, as shown in the phase III B-SIMPLE4 trial.

Real-world patients with psoriatic arthritis (PsA) who received and remained on secukinumab treatment for 6 months has attained minimal disease activity (MDA) and shown improvements in clinical manifestations, patient-reported outcomes, and work productivity at follow-up, reveals a study. The results are consistent with findings from clinical trials.

Once-weekly treatment with tirzepatide in adults with obesity appears to yield substantial and sustained reductions in body weight, according to the phase III SURMOUNT-1 trial.